Bayer's Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer
- Details
- Category: Bayer
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy).
Abbott's HUMIRA® (adalimumab) receives FDA approval for the treatment of ulcerative colitis
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.
Bayer joins global initiative for better access to safe and effective contraception
- Details
- Category: Bayer
A new initiative announced at the United Nations headquarters in New York by Norwegian Prime Minister Jens Stoltenberg shall make a safe and effective long-acting and reversible method available to more than 27 million women in the world's poorest nations.
Abbott announces international launch of the Absorb(TM)
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that Absorb(TM), the world's first drug eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America. Absorb is a first-of-its-kind device for the treatment of coronary artery disease (CAD).
Novo Nordisk invests further in China
- Details
- Category: Novo Nordisk
As the first multinational company to open a research centre in China in 1997, Novo Nordisk now reaffirms its long-term commitment to the country by investing an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing.
Vanderbilt University and Bristol-Myers Squibb sign collaboration agreement to develop novel treatments for parkinson's Disease
- Details
- Category: Bristol-Myers Squibb
Vanderbilt University and Bristol-Myers Squibb Company (NYSE:BMY) have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson's disease.
Novo Nordisk ranks 4th among the world's top 20 science employers
- Details
- Category: Novo Nordisk
Novo Nordisk was just ranked number four on the Science 2012 Top Employer list - up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.
More Pharma News ...
- Boehringer Ingelheim launches beta social game Syrum to promote science and innovation
- Roche leads healthcare sector in key sustainability index for fourth consecutive year
- Boehringer Ingelheim and Lilly introduce the My Well Planner lifestyle improvement program
- First efficacy results for dengue vaccine candidate
- Bayer HealthCare starts special lab space-model CoLaborator™ for promising life science companies
- Boehringer Ingelheim and the ETH Zurich announce diabetes and obesity research collaboration
- Abbott to collaborate with Astellas in CMV vaccine trial